ROYALTY PHARMA PLC- CL A (RPRX) Fundamental Analysis & Valuation

NASDAQ:RPRX • GB00BMVP7Y09

Current stock price

48.57 USD
+0.08 (+0.16%)
At close:
48.57 USD
0 (0%)
After Hours:

This RPRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. RPRX Profitability Analysis

1.1 Basic Checks

  • In the past year RPRX was profitable.
  • In the past year RPRX had a positive cash flow from operations.
  • RPRX had positive earnings in each of the past 5 years.
  • In the past 5 years RPRX always reported a positive cash flow from operatings.
RPRX Yearly Net Income VS EBIT VS OCF VS FCFRPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 3.93%, RPRX belongs to the top of the industry, outperforming 84.90% of the companies in the same industry.
  • RPRX has a Return On Equity of 11.90%. This is amongst the best in the industry. RPRX outperforms 85.94% of its industry peers.
  • RPRX has a better Return On Invested Capital (6.49%) than 83.33% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for RPRX is significantly below the industry average of 13.06%.
Industry RankSector Rank
ROA 3.93%
ROE 11.9%
ROIC 6.49%
ROA(3y)5.19%
ROA(5y)3.87%
ROE(3y)13.89%
ROE(5y)10.63%
ROIC(3y)6.59%
ROIC(5y)6.19%
RPRX Yearly ROA, ROE, ROICRPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • RPRX's Profit Margin of 32.42% is amongst the best of the industry. RPRX outperforms 95.31% of its industry peers.
  • In the last couple of years the Profit Margin of RPRX has grown nicely.
  • RPRX has a better Operating Margin (65.58%) than 100.00% of its industry peers.
  • RPRX's Operating Margin has declined in the last couple of years.
Industry RankSector Rank
OM 65.58%
PM (TTM) 32.42%
GM N/A
OM growth 3Y16.71%
OM growth 5Y-3.47%
PM growth 3Y156.85%
PM growth 5Y6.8%
GM growth 3YN/A
GM growth 5YN/A
RPRX Yearly Profit, Operating, Gross MarginsRPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 50 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. RPRX Health Analysis

2.1 Basic Checks

  • RPRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • RPRX has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for RPRX has been increased compared to 5 years ago.
  • RPRX has a worse debt/assets ratio than last year.
RPRX Yearly Shares OutstandingRPRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
RPRX Yearly Total Debt VS Total AssetsRPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • An Altman-Z score of 1.89 indicates that RPRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 1.89, RPRX is in the better half of the industry, outperforming 61.98% of the companies in the same industry.
  • The Debt to FCF ratio of RPRX is 11.30, which is on the high side as it means it would take RPRX, 11.30 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 11.30, RPRX is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
  • A Debt/Equity ratio of 1.32 is on the high side and indicates that RPRX has dependencies on debt financing.
  • The Debt to Equity ratio of RPRX (1.32) is worse than 74.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF 11.3
Altman-Z 1.89
ROIC/WACC0.75
WACC8.64%
RPRX Yearly LT Debt VS Equity VS FCFRPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B

2.3 Liquidity

  • RPRX has a Current Ratio of 2.40. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.40, RPRX is in line with its industry, outperforming 44.79% of the companies in the same industry.
  • A Quick Ratio of 2.40 indicates that RPRX has no problem at all paying its short term obligations.
  • RPRX has a Quick ratio (2.40) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2.4
RPRX Yearly Current Assets VS Current LiabilitesRPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RPRX Growth Analysis

3.1 Past

  • RPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.05%, which is quite good.
  • The Earnings Per Share has been growing slightly by 0.60% on average over the past years.
  • RPRX shows a small growth in Revenue. In the last year, the Revenue has grown by 5.06%.
  • Measured over the past years, RPRX shows a small growth in Revenue. The Revenue has been growing by 2.30% on average per year.
EPS 1Y (TTM)8.05%
EPS 3Y6.47%
EPS 5Y0.6%
EPS Q2Q%27.83%
Revenue 1Y (TTM)5.06%
Revenue growth 3Y2.06%
Revenue growth 5Y2.3%
Sales Q2Q%4.71%

3.2 Future

  • RPRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.16% yearly.
  • The Revenue is expected to grow by 10.01% on average over the next years. This is quite good.
EPS Next Y16.65%
EPS Next 2Y11.8%
EPS Next 3Y11.89%
EPS Next 5Y12.16%
Revenue Next Year4.05%
Revenue Next 2Y4.43%
Revenue Next 3Y5.93%
Revenue Next 5Y10.01%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RPRX Yearly Revenue VS EstimatesRPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B 5B
RPRX Yearly EPS VS EstimatesRPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

8

4. RPRX Valuation Analysis

4.1 Price/Earnings Ratio

  • RPRX is valuated reasonably with a Price/Earnings ratio of 10.96.
  • Compared to the rest of the industry, the Price/Earnings ratio of RPRX indicates a rather cheap valuation: RPRX is cheaper than 89.06% of the companies listed in the same industry.
  • RPRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.17.
  • With a Price/Forward Earnings ratio of 9.40, the valuation of RPRX can be described as very reasonable.
  • RPRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. RPRX is cheaper than 90.10% of the companies in the same industry.
  • RPRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.05, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 10.96
Fwd PE 9.4
RPRX Price Earnings VS Forward Price EarningsRPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, RPRX is valued cheaper than 80.73% of the companies in the same industry.
Industry RankSector Rank
P/FCF 35.37
EV/EBITDA N/A
RPRX Per share dataRPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of RPRX may justify a higher PE ratio.
PEG (NY)0.66
PEG (5Y)18.31
EPS Next 2Y11.8%
EPS Next 3Y11.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. RPRX Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 2.03%, RPRX has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 0.64, RPRX pays a better dividend. On top of this RPRX pays more dividend than 92.71% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, RPRX has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.03%

5.2 History

  • RPRX has been paying a dividend for over 5 years, so it has already some track record.
  • RPRX has not decreased its dividend in the past 5 years, so it has a somewhat stable track record.
Dividend Growth(5Y)N/A
Div Incr Years5
Div Non Decr Years5
RPRX Yearly Dividends per shareRPRX Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • RPRX pays out 49.06% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP49.06%
EPS Next 2Y11.8%
EPS Next 3Y11.89%
RPRX Yearly Income VS Free CF VS DividendRPRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B
RPRX Dividend Payout.RPRX Dividend Payout, showing the Payout Ratio.RPRX Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

RPRX Fundamentals: All Metrics, Ratios and Statistics

ROYALTY PHARMA PLC- CL A

NASDAQ:RPRX (4/2/2026, 8:00:02 PM)

After market: 48.57 0 (0%)

48.57

+0.08 (+0.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11
Earnings (Next)05-06
Inst Owners87.31%
Inst Owner Change0%
Ins Owners1.59%
Ins Owner Change8.12%
Market Cap28.02B
Revenue(TTM)2.38B
Net Income(TTM)770.95M
Analysts83.75
Price Target53.03 (9.18%)
Short Float %2.92%
Short Ratio3.17
Dividend
Industry RankSector Rank
Dividend Yield 2.03%
Yearly Dividend0.65
Dividend Growth(5Y)N/A
DP49.06%
Div Incr Years5
Div Non Decr Years5
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.34%
Min EPS beat(2)8.69%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-9.55%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.66%
EPS beat(12)9
Avg EPS beat(12)0.82%
EPS beat(16)10
Avg EPS beat(16)-0.51%
Revenue beat(2)1
Avg Revenue beat(2)-7.72%
Min Revenue beat(2)-23.38%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)-0.41%
Min Revenue beat(4)-23.38%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-7.18%
Revenue beat(12)3
Avg Revenue beat(12)-9.25%
Revenue beat(16)3
Avg Revenue beat(16)-10.51%
PT rev (1m)1.22%
PT rev (3m)14.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.2%
Revenue NQ rev (1m)0.76%
Revenue NQ rev (3m)93.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.14%
Valuation
Industry RankSector Rank
PE 10.96
Fwd PE 9.4
P/S 11.78
P/FCF 35.37
P/OCF 11.25
P/B 4.33
P/tB 5.05
EV/EBITDA N/A
EPS(TTM)4.43
EY9.12%
EPS(NY)5.17
Fwd EY10.64%
FCF(TTM)1.37
FCFY2.83%
OCF(TTM)4.32
OCFY8.89%
SpS4.12
BVpS11.23
TBVpS9.62
PEG (NY)0.66
PEG (5Y)18.31
Graham Number33.45
Profitability
Industry RankSector Rank
ROA 3.93%
ROE 11.9%
ROCE 8.21%
ROIC 6.49%
ROICexc 7.04%
ROICexgc 7.44%
OM 65.58%
PM (TTM) 32.42%
GM N/A
FCFM 33.31%
ROA(3y)5.19%
ROA(5y)3.87%
ROE(3y)13.89%
ROE(5y)10.63%
ROIC(3y)6.59%
ROIC(5y)6.19%
ROICexc(3y)7.21%
ROICexc(5y)6.98%
ROICexgc(3y)7.34%
ROICexgc(5y)7.06%
ROCE(3y)8.34%
ROCE(5y)7.84%
ROICexgc growth 3Y10.47%
ROICexgc growth 5Y-5.87%
ROICexc growth 3Y8.49%
ROICexc growth 5Y-6.85%
OM growth 3Y16.71%
OM growth 5Y-3.47%
PM growth 3Y156.85%
PM growth 5Y6.8%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF 11.3
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 71.39%
Interest Coverage -5.64
Cash Conversion N/A
Profit Quality 102.74%
Current Ratio 2.4
Quick Ratio 2.4
Altman-Z 1.89
F-Score5
WACC8.64%
ROIC/WACC0.75
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)90.64%
Cap/Sales(5y)89.1%
Profit Quality(3y)70.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.05%
EPS 3Y6.47%
EPS 5Y0.6%
EPS Q2Q%27.83%
EPS Next Y16.65%
EPS Next 2Y11.8%
EPS Next 3Y11.89%
EPS Next 5Y12.16%
Revenue 1Y (TTM)5.06%
Revenue growth 3Y2.06%
Revenue growth 5Y2.3%
Sales Q2Q%4.71%
Revenue Next Year4.05%
Revenue Next 2Y4.43%
Revenue Next 3Y5.93%
Revenue Next 5Y10.01%
EBIT growth 1Y20.66%
EBIT growth 3Y19.11%
EBIT growth 5Y-1.25%
EBIT Next Year13.04%
EBIT Next 3Y10.82%
EBIT Next 5Y10.98%
FCF growth 1Y200.85%
FCF growth 3Y25.33%
FCF growth 5YN/A
OCF growth 1Y-10.08%
OCF growth 3Y5.11%
OCF growth 5Y4.12%

ROYALTY PHARMA PLC- CL A / RPRX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?

ChartMill assigns a fundamental rating of 6 / 10 to RPRX.


What is the valuation status for RPRX stock?

ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.


What is the profitability of RPRX stock?

ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.


What is the earnings growth outlook for ROYALTY PHARMA PLC- CL A?

The Earnings per Share (EPS) of ROYALTY PHARMA PLC- CL A (RPRX) is expected to grow by 16.65% in the next year.


How sustainable is the dividend of ROYALTY PHARMA PLC- CL A (RPRX) stock?

The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 5 / 10 and the dividend payout ratio is 49.06%.